<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36787643</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-4804</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>23</Day></PubDate></JournalIssue><Title>Journal of medicinal chemistry</Title><ISOAbbreviation>J Med Chem</ISOAbbreviation></Journal><ArticleTitle>A Medicinal Chemistry Perspective on Excitatory Amino Acid Transporter 2 Dysfunction in Neurodegenerative Diseases.</ArticleTitle><Pagination><StartPage>2330</StartPage><EndPage>2346</EndPage><MedlinePgn>2330-2346</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jmedchem.2c01572</ELocationID><Abstract><AbstractText>The excitatory amino acid transporter 2 (EAAT2) plays a key role in the clearance and recycling of glutamate - the major excitatory neurotransmitter in the mammalian brain. EAAT2 loss/dysfunction triggers a cascade of neurodegenerative events, comprising glutamatergic excitotoxicity and neuronal death. Nevertheless, our current knowledge regarding EAAT2 in neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD), is restricted to post-mortem analysis of brain tissue and experimental models. Thus, detecting EAAT2 in the living human brain might be crucial to improve diagnosis/therapy for ALS and AD. This perspective article describes the role of EAAT2 in physio/pathological processes and provides a structure-activity relationship of EAAT2-binders, bringing two perspectives: therapy (activators) and diagnosis (molecular imaging tools).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fontana</LastName><ForeName>Igor C</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering and Imaging Sciences, St Thomas' Hospital, King's College London, London SE1 7EH, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600, 90035-003 Porto Alegre, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Blickag&#xe5;ngen 16 - Neo floor seventh, 141 83 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Souza</LastName><ForeName>D&#xe9;bora G</ForeName><Initials>DG</Initials><Identifier Source="ORCID">0000-0003-2982-4989</Identifier><AffiliationInfo><Affiliation>Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600, 90035-003 Porto Alegre, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Institute of Rio Grande do Sul, Pontifical Catholic University of Rio Grande do Sul, Av. Ipiranga, 6681 Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Souza</LastName><ForeName>Diogo O</ForeName><Initials>DO</Initials><AffiliationInfo><Affiliation>Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600, 90035-003 Porto Alegre, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600, 90035-003 Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gee</LastName><ForeName>Antony</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8389-9012</Identifier><AffiliationInfo><Affiliation>School of Biomedical Engineering and Imaging Sciences, St Thomas' Hospital, King's College London, London SE1 7EH, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimmer</LastName><ForeName>Eduardo R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600, 90035-003 Porto Alegre, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, Universidade Federal do Rio Grande do Sul, Av. Sarmento Leite 500, sala, 90035-003 Porto Alegre, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Program in Biological Sciences: Biochemistry (PPGBioq), and Pharmacology and Therapeutics (PPGFT), Universidade Federal do Rio Grande do Sul, Av. Sarmento Leite 500, sala, 305 Porto Alegre, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Institute of Rio Grande do Sul, Pontifical Catholic University of Rio Grande do Sul, Av. Ipiranga, 6681 Porto Alegre, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McGill University Research Centre for Studies in Aging, McGill University, Montreal, Quebec H4H 1R3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bongarzone</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1309-3045</Identifier><AffiliationInfo><Affiliation>School of Biomedical Engineering and Imaging Sciences, St Thomas' Hospital, King's College London, London SE1 7EH, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>WT203148/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Chem</MedlineTA><NlmUniqueID>9716531</NlmUniqueID><ISSNLinking>0022-2623</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D027342">Excitatory Amino Acid Transporter 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Med Chem. 2023 Mar 23;66(6):4271</RefSource><PMID Version="1">36917065</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D027342" MajorTopicYN="N">Excitatory Amino Acid Transporter 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008322" MajorTopicYN="N">Mammals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors
declare the following competing financial interest(s): E.R.Z. serves
on the scientific advisory board of Next Innovative Therapeutics (Nintx).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>14</Day><Hour>17</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36787643</ArticleId><ArticleId IdType="pmc">PMC9969404</ArticleId><ArticleId IdType="doi">10.1021/acs.jmedchem.2c01572</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Deco G.; et al. How local excitation-inhibition ratio impacts the whole brain dynamics. J. Neurosci. 2014, 34, 7886&#x2013;7898. 10.1523/JNEUROSCI.5068-13.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5068-13.2014</ArticleId><ArticleId IdType="pmc">PMC4044249</ArticleId><ArticleId IdType="pubmed">24899711</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonnum F. Glutamate: a neurotransmitter in mammalian brain. J. Neurochem. 1984, 42, 1&#x2013;11. 10.1111/j.1471-4159.1984.tb09689.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1984.tb09689.x</ArticleId><ArticleId IdType="pubmed">6139418</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkins R. A. The blood-brain barrier and glutamate. Am. J. Clin. Nutr. 2009, 90, 867S&#x2013;874S. 10.3945/ajcn.2009.27462BB.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/ajcn.2009.27462BB</ArticleId><ArticleId IdType="pmc">PMC3136011</ArticleId><ArticleId IdType="pubmed">19571220</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira G. C.; et al. Metabolism of [1,6-(13) C]glucose in the cerebellum of 18-day-old rats: Comparison with cerebral metabolism. J. Neurochem. 2021, 157, 1946&#x2013;1962. 10.1111/jnc.15326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15326</ArticleId><ArticleId IdType="pmc">PMC9733799</ArticleId><ArticleId IdType="pubmed">33619759</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman D. L.; et al. 13C MRS studies of neuroenergetics and neurotransmitter cycling in humans. NMR Biomed. 2011, 24, 943&#x2013;957. 10.1002/nbm.1772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/nbm.1772</ArticleId><ArticleId IdType="pmc">PMC3651027</ArticleId><ArticleId IdType="pubmed">21882281</ArticleId></ArticleIdList></Reference><Reference><Citation>Erecinska M.; Silver I. A. Metabolism and role of glutamate in mammalian brain. Prog. Neurobiol. 1990, 35, 245&#x2013;296. 10.1016/0301-0082(90)90013-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0301-0082(90)90013-7</ArticleId><ArticleId IdType="pubmed">1980745</ArticleId></ArticleIdList></Reference><Reference><Citation>Gegelashvili G.; Schousboe A. High affinity glutamate transporters: regulation of expression and activity. Mol. Pharmacol. 1997, 52, 6&#x2013;15. 10.1124/mol.52.1.6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.52.1.6</ArticleId><ArticleId IdType="pubmed">9224806</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornsen L. P.; et al. The GLT-1 (EAAT2; slc1a2) glutamate transporter is essential for glutamate homeostasis in the neocortex of the mouse. J. Neurochem. 2014, 128, 641&#x2013;649. 10.1111/jnc.12509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12509</ArticleId><ArticleId IdType="pubmed">24224925</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J. D.; et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996, 16, 675&#x2013;686. 10.1016/S0896-6273(00)80086-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80086-0</ArticleId><ArticleId IdType="pubmed">8785064</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdul H. M.; et al. Cognitive decline in Alzheimer&#x2019;s disease is associated with selective changes in calcineurin/NFAT signaling. J. Neurosci. 2009, 29, 12957&#x2013;12969. 10.1523/JNEUROSCI.1064-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1064-09.2009</ArticleId><ArticleId IdType="pmc">PMC2782445</ArticleId><ArticleId IdType="pubmed">19828810</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanoni C.; et al. Increased internalisation and degradation of GLT-1 glial glutamate transporter in a cell model for familial amyotrophic lateral sclerosis (ALS). J. Cell. Sci. 2004, 117, 5417&#x2013;5426. 10.1242/jcs.01411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.01411</ArticleId><ArticleId IdType="pubmed">15466883</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donovan S. M.; et al. The role of glutamate transporters in the pathophysiology of neuropsychiatric disorders. NPJ. Schizophr. 2017, 3, 32.10.1038/s41537-017-0037-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41537-017-0037-1</ArticleId><ArticleId IdType="pmc">PMC5608761</ArticleId><ArticleId IdType="pubmed">28935880</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A.; et al. Divergent roles of astrocytic versus neuronal EAAT2 deficiency on cognition and overlap with aging and Alzheimer&#x2019;s molecular signatures. Proc. Natl. Acad. Sci. U. S. A. 2019, 116, 21800&#x2013;21811. 10.1073/pnas.1903566116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1903566116</ArticleId><ArticleId IdType="pmc">PMC6815169</ArticleId><ArticleId IdType="pubmed">31591195</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J. D.; et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 1995, 38, 73&#x2013;84. 10.1002/ana.410380114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410380114</ArticleId><ArticleId IdType="pubmed">7611729</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E.; et al. Deficient glutamate transport is associated with neurodegeneration in Alzheimer&#x2019;s disease. Ann. Neurol. 1996, 40, 759&#x2013;766. 10.1002/ana.410400512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410400512</ArticleId><ArticleId IdType="pubmed">8957017</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.; et al. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J. Cell. Physiol. 2011, 226, 2484&#x2013;2493. 10.1002/jcp.22609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.22609</ArticleId><ArticleId IdType="pmc">PMC3130100</ArticleId><ArticleId IdType="pubmed">21792905</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkin G. M.; et al. Glutamate transporters, EAAT1 and EAAT2, are potentially important in the pathophysiology and treatment of schizophrenia and affective disorders. World J. Psychiatry 2018, 8, 51&#x2013;63. 10.5498/wjp.v8.i2.51.</Citation><ArticleIdList><ArticleId IdType="doi">10.5498/wjp.v8.i2.51</ArticleId><ArticleId IdType="pmc">PMC6033743</ArticleId><ArticleId IdType="pubmed">29988908</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontana A. C. Current approaches to enhance glutamate transporter function and expression. J. Neurochem. 2015, 134, 982&#x2013;1007. 10.1111/jnc.13200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13200</ArticleId><ArticleId IdType="pubmed">26096891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zielke H. R.; et al. Compartmentation of [14C]glutamate and [14C]glutamine oxidative metabolism in the rat hippocampus as determined by microdialysis. J. Neurochem. 1998, 71, 1315&#x2013;1320. 10.1046/j.1471-4159.1998.71031315.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1998.71031315.x</ArticleId><ArticleId IdType="pubmed">9721758</ArticleId></ArticleIdList></Reference><Reference><Citation>Shegani A.; et al. Radiosynthesis, Preclinical, and Clinical Positron Emission Tomography Studies of Carbon-11 Labeled Endogenous and Natural Exogenous Compounds. Chem. Rev. 2023, 123, 105.10.1021/acs.chemrev.2c00398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.2c00398</ArticleId><ArticleId IdType="pmc">PMC9837829</ArticleId><ArticleId IdType="pubmed">36399832</ArticleId></ArticleIdList></Reference><Reference><Citation>Meldrum B. S. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J. Nutr. 2000, 130, 1007S&#x2013;1015S. 10.1093/jn/130.4.1007S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jn/130.4.1007S</ArticleId><ArticleId IdType="pubmed">10736372</ArticleId></ArticleIdList></Reference><Reference><Citation>Petroff O. A. GABA and glutamate in the human brain. Neuroscientist 2002, 8, 562&#x2013;573. 10.1177/1073858402238515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858402238515</ArticleId><ArticleId IdType="pubmed">12467378</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiner A.; Levitz J. Glutamatergic Signaling in the Central Nervous System: Ionotropic and Metabotropic Receptors in Concert. Neuron 2018, 98, 1080&#x2013;1098. 10.1016/j.neuron.2018.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.05.018</ArticleId><ArticleId IdType="pmc">PMC6484838</ArticleId><ArticleId IdType="pubmed">29953871</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedergaard M.; et al. Beyond the role of glutamate as a neurotransmitter. Nat. Rev. Neurosci. 2002, 3, 748&#x2013;755. 10.1038/nrn916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn916</ArticleId><ArticleId IdType="pubmed">12209123</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakanishi S.; et al. Glutamate receptors: brain function and signal transduction. Brain Res. Brain Res. Rev. 1998, 26, 230&#x2013;235. 10.1016/S0165-0173(97)00033-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-0173(97)00033-7</ArticleId><ArticleId IdType="pubmed">9651535</ArticleId></ArticleIdList></Reference><Reference><Citation>Amara S. G.; Fontana A. C. Excitatory amino acid transporters: keeping up with glutamate. Neurochem. Int. 2002, 41, 313&#x2013;318. 10.1016/S0197-0186(02)00018-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-0186(02)00018-9</ArticleId><ArticleId IdType="pubmed">12176072</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W.; et al. The glutamate transporter GLT1a is expressed in excitatory axon terminals of mature hippocampal neurons. J. Neurosci. 2004, 24, 1136&#x2013;1148. 10.1523/JNEUROSCI.1586-03.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1586-03.2004</ArticleId><ArticleId IdType="pmc">PMC2849838</ArticleId><ArticleId IdType="pubmed">14762132</ArticleId></ArticleIdList></Reference><Reference><Citation>Storck T.; et al. Structure, expression, and functional analysis of a Na(+)-dependent glutamate/aspartate transporter from rat brain. Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 10955&#x2013;10959. 10.1073/pnas.89.22.10955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.22.10955</ArticleId><ArticleId IdType="pmc">PMC50461</ArticleId><ArticleId IdType="pubmed">1279699</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai Y.; Hediger M. A. Primary structure and functional characterization of a high-affinity glutamate transporter. Nature 1992, 360, 467&#x2013;471. 10.1038/360467a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/360467a0</ArticleId><ArticleId IdType="pubmed">1280334</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairman W. A.; et al. An excitatory amino-acid transporter with properties of a ligand-gated chloride channel. Nature 1995, 375, 599&#x2013;603. 10.1038/375599a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/375599a0</ArticleId><ArticleId IdType="pubmed">7791878</ArticleId></ArticleIdList></Reference><Reference><Citation>Wersinger E.; et al. The glutamate transporter EAAT5 works as a presynaptic receptor in mouse rod bipolar cells. J. Physiol. 2006, 577, 221&#x2013;234. 10.1113/jphysiol.2006.118281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2006.118281</ArticleId><ArticleId IdType="pmc">PMC2000664</ArticleId><ArticleId IdType="pubmed">16973698</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehre K. P.; et al. Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations. J. Neurosci. 1995, 15, 1835&#x2013;1853. 10.1523/JNEUROSCI.15-03-01835.1995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.15-03-01835.1995</ArticleId><ArticleId IdType="pmc">PMC6578153</ArticleId><ArticleId IdType="pubmed">7891138</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu B. Cryo-EM structures of excitatory amino acid transporter 3 visualize coupled substrate, sodium, and proton binding and transport. Sci. Adv. 2021, 7, eabf5814.10.1126/sciadv.abf5814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abf5814</ArticleId><ArticleId IdType="pmc">PMC7929514</ArticleId><ArticleId IdType="pubmed">33658209</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagao S.; et al. EAAT4, a glutamate transporter with properties of a chloride channel, is predominantly localized in Purkinje cell dendrites, and forms parasagittal compartments in rat cerebellum. Neuroscience 1997, 78, 929&#x2013;933. 10.1016/S0306-4522(97)00021-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(97)00021-3</ArticleId><ArticleId IdType="pubmed">9174061</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms H. C. C.; et al. Glutamate Transporters in the Blood-Brain Barrier. Adv. Neurobiol. 2017, 16, 297&#x2013;314. 10.1007/978-3-319-55769-4_15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-55769-4_15</ArticleId><ArticleId IdType="pubmed">28828617</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriza J. L.; et al. Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance. Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 4155&#x2013;4160. 10.1073/pnas.94.8.4155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.8.4155</ArticleId><ArticleId IdType="pmc">PMC20584</ArticleId><ArticleId IdType="pubmed">9108121</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka K.; et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 1997, 276, 1699&#x2013;1702. 10.1126/science.276.5319.1699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.276.5319.1699</ArticleId><ArticleId IdType="pubmed">9180080</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergles D. E.; et al. Comparison of coupled and uncoupled currents during glutamate uptake by GLT-1 transporters. J. Neurosci. 2002, 22, 10153&#x2013;10162. 10.1523/JNEUROSCI.22-23-10153.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-23-10153.2002</ArticleId><ArticleId IdType="pmc">PMC6758767</ArticleId><ArticleId IdType="pubmed">12451116</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimmele T. S.; Rosenberg P. A. GLT-1: The elusive presynaptic glutamate transporter. Neurochem. Int. 2016, 98, 19&#x2013;28. 10.1016/j.neuint.2016.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2016.04.010</ArticleId><ArticleId IdType="pmc">PMC5070539</ArticleId><ArticleId IdType="pubmed">27129805</ArticleId></ArticleIdList></Reference><Reference><Citation>Yernool D.; et al. Structure of a glutamate transporter homologue from Pyrococcus horikoshii. Nature 2004, 431, 811&#x2013;818. 10.1038/nature03018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03018</ArticleId><ArticleId IdType="pubmed">15483603</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes N.; et al. Transport mechanism of a bacterial homologue of glutamate transporters. Nature 2009, 462, 880&#x2013;885. 10.1038/nature08616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08616</ArticleId><ArticleId IdType="pmc">PMC2934767</ArticleId><ArticleId IdType="pubmed">19924125</ArticleId></ArticleIdList></Reference><Reference><Citation>Underhill S. M.; et al. Differential regulation of two isoforms of the glial glutamate transporter EAAT2 by DLG1 and CaMKII. J. Neurosci. 2015, 35, 5260&#x2013;5270. 10.1523/JNEUROSCI.4365-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4365-14.2015</ArticleId><ArticleId IdType="pmc">PMC4380999</ArticleId><ArticleId IdType="pubmed">25834051</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmseth S.; et al. The concentrations and distributions of three C-terminal variants of the GLT1 (EAAT2; slc1a2) glutamate transporter protein in rat brain tissue suggest differential regulation. Neuroscience 2009, 162, 1055&#x2013;1071. 10.1016/j.neuroscience.2009.03.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2009.03.048</ArticleId><ArticleId IdType="pubmed">19328838</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauriat T. L.; et al. Quantitative analysis of glutamate transporter mRNA expression in prefrontal and primary visual cortex in normal and schizophrenic brain. Neuroscience 2006, 137, 843&#x2013;851. 10.1016/j.neuroscience.2005.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2005.10.003</ArticleId><ArticleId IdType="pubmed">16297566</ArticleId></ArticleIdList></Reference><Reference><Citation>Milton I. D.; et al. Expression of the glial glutamate transporter EAAT2 in the human CNS: an immunohistochemical study. Brain Res. Mol. Brain Res. 1997, 52, 17&#x2013;31. 10.1016/S0169-328X(97)00233-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-328X(97)00233-7</ArticleId><ArticleId IdType="pubmed">9450673</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehre K. P.; Danbolt N. C. The number of glutamate transporter subtype molecules at glutamatergic synapses: chemical and stereological quantification in young adult rat brain. J. Neurosci. 1998, 18, 8751&#x2013;8757. 10.1523/JNEUROSCI.18-21-08751.1998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.18-21-08751.1998</ArticleId><ArticleId IdType="pmc">PMC6793562</ArticleId><ArticleId IdType="pubmed">9786982</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J.; Amara S. G. New views of glutamate transporter structure and function: advances and challenges. Neuropharmacology 2011, 60, 172&#x2013;181. 10.1016/j.neuropharm.2010.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2010.07.019</ArticleId><ArticleId IdType="pmc">PMC3082951</ArticleId><ArticleId IdType="pubmed">20708631</ArticleId></ArticleIdList></Reference><Reference><Citation>Teichman S.; Kanner B. I. Aspartate-444 is essential for productive substrate interactions in a neuronal glutamate transporter. J. Gen. Physiol. 2007, 129, 527&#x2013;539. 10.1085/jgp.200609707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1085/jgp.200609707</ArticleId><ArticleId IdType="pmc">PMC2151622</ArticleId><ArticleId IdType="pubmed">17535962</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudker O.; et al. Coupling substrate and ion binding to extracellular gate of a sodium-dependent aspartate transporter. Nature 2007, 445, 387&#x2013;393. 10.1038/nature05455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05455</ArticleId><ArticleId IdType="pubmed">17230192</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z.; et al. Structural basis of ligand binding modes of human EAAT2. Nat. Commun. 2022, 13, 3329.10.1038/s41467-022-31031-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31031-x</ArticleId><ArticleId IdType="pmc">PMC9184463</ArticleId><ArticleId IdType="pubmed">35680945</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato T.; et al. Structural insights into inhibitory mechanism of human excitatory amino acid transporter EAAT2. Nat. Commun. 2022, 13, 4714.10.1038/s41467-022-32442-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32442-6</ArticleId><ArticleId IdType="pmc">PMC9372063</ArticleId><ArticleId IdType="pubmed">35953475</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortensen O. V.; et al. Molecular determinants of transport stimulation of EAAT2 are located at interface between the trimerization and substrate transport domains. J. Neurochem. 2015, 133, 199&#x2013;210. 10.1111/jnc.13047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13047</ArticleId><ArticleId IdType="pubmed">25626691</ArticleId></ArticleIdList></Reference><Reference><Citation>Damm-Ganamet K. L.; et al. A computational approach yields selective inhibitors of human excitatory amino acid transporter 2 (EAAT2). J. Biol. Chem. 2020, 295, 4359&#x2013;4366. 10.1074/jbc.AC119.011190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.AC119.011190</ArticleId><ArticleId IdType="pmc">PMC7105306</ArticleId><ArticleId IdType="pubmed">32079674</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonafede R.; Mariotti R. ALS Pathogenesis and Therapeutic Approaches: The Role of Mesenchymal Stem Cells and Extracellular Vesicles. Front Cell Neurosci. 2017, 11, 80.10.3389/fncel.2017.00080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00080</ArticleId><ArticleId IdType="pmc">PMC5359305</ArticleId><ArticleId IdType="pubmed">28377696</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldink J. H. ALS genetic epidemiology &#x2019;How simplex is the genetic epidemiology of ALS?&#x2019;. J. Neurol. Neurosurg. Psychiatry 2017, 88, 537.10.1136/jnnp-2016-315469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315469</ArticleId><ArticleId IdType="pubmed">28209650</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M.; et al. Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease. Hum. Mol. Genet. 2009, 18, 3217&#x2013;3226. 10.1093/hmg/ddp260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp260</ArticleId><ArticleId IdType="pmc">PMC2722984</ArticleId><ArticleId IdType="pubmed">19483195</ArticleId></ArticleIdList></Reference><Reference><Citation>Benbrika S.; et al. Cognitive, Emotional and Psychological Manifestations in Amyotrophic Lateral Sclerosis at Baseline and Overtime: A Review. Front Neurosci. 2019, 13, 951.10.3389/fnins.2019.00951.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00951</ArticleId><ArticleId IdType="pmc">PMC6746914</ArticleId><ArticleId IdType="pubmed">31551700</ArticleId></ArticleIdList></Reference><Reference><Citation>Charles T.; Swash M. Amyotrophic lateral sclerosis: current understanding. J. Neurosci. Nurs. 2001, 33, 245&#x2013;253. 10.1097/01376517-200110000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01376517-200110000-00005</ArticleId><ArticleId IdType="pubmed">11668883</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J. D.; et al. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med. 1992, 326, 1464&#x2013;1468. 10.1056/NEJM199205283262204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199205283262204</ArticleId><ArticleId IdType="pubmed">1349424</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C. L.; et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998, 20, 589&#x2013;602. 10.1016/S0896-6273(00)80997-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80997-6</ArticleId><ArticleId IdType="pubmed">9539131</ArticleId></ArticleIdList></Reference><Reference><Citation>Flomen R.; Makoff A. Increased RNA editing in EAAT2 pre-mRNA from amyotrophic lateral sclerosis patients: involvement of a cryptic polyadenylation site. Neurosci. Lett. 2011, 497, 139&#x2013;143. 10.1016/j.neulet.2011.04.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2011.04.047</ArticleId><ArticleId IdType="pubmed">21569822</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson M.; et al. Polymorphisms in the glutamate transporter gene EAAT2 in European ALS patients. J. Neurol. 1999, 246, 1140&#x2013;1144. 10.1007/s004150050532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004150050532</ArticleId><ArticleId IdType="pubmed">10653305</ArticleId></ArticleIdList></Reference><Reference><Citation>Flowers J. M.; et al. Intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis. Ann. Neurol. 2001, 49, 643&#x2013;649. 10.1002/ana.1029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.1029</ArticleId><ArticleId IdType="pubmed">11357955</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es M. A.; et al. Amyotrophic lateral sclerosis. Lancet 2017, 390, 2084&#x2013;2098. 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M. E.; et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994, 264, 1772&#x2013;1775. 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland D. S.; et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 1604&#x2013;1609. 10.1073/pnas.032539299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.032539299</ArticleId><ArticleId IdType="pmc">PMC122237</ArticleId><ArticleId IdType="pubmed">11818550</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Y.; et al. Extensive dysregulations of oligodendrocytic and astrocytic connexins are associated with disease progression in an amyotrophic lateral sclerosis mouse model. J. Neurochem. 2014, 11, 42.10.1186/1742-2094-11-42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-42</ArticleId><ArticleId IdType="pmc">PMC4016493</ArticleId><ArticleId IdType="pubmed">24597481</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallis N.; et al. Combined excitotoxic-oxidative stress and the concept of non-cell autonomous pathology of ALS: insights into motoneuron axonopathy and astrogliosis. Neurochem. Int. 2012, 61, 523&#x2013;530. 10.1016/j.neuint.2012.02.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2012.02.026</ArticleId><ArticleId IdType="pubmed">22421531</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas M. R.; Johnson J. A. Astrogliosis in amyotrophic lateral sclerosis: role and therapeutic potential of astrocytes. Neurotherapeutics 2010, 7, 471&#x2013;481. 10.1016/j.nurt.2010.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nurt.2010.05.012</ArticleId><ArticleId IdType="pmc">PMC2967019</ArticleId><ArticleId IdType="pubmed">20880509</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine S. M.; et al. Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia. J. Biol. Chem. 1996, 271, 15303&#x2013;15306. 10.1074/jbc.271.26.15303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.26.15303</ArticleId><ArticleId IdType="pubmed">8663435</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L. L.; et al. Membralin deficiency dysregulates astrocytic glutamate homeostasis leading to ALS-like impairment. J. Clin. Invest. 2019, 129, 3103&#x2013;3120. 10.1172/JCI127695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI127695</ArticleId><ArticleId IdType="pmc">PMC6668683</ArticleId><ArticleId IdType="pubmed">31112137</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibb S. L.; et al. A caspase-3-cleaved fragment of the glial glutamate transporter EAAT2 is sumoylated and targeted to promyelocytic leukemia nuclear bodies in mutant SOD1-linked amyotrophic lateral sclerosis. J. Biol. Chem. 2007, 282, 32480&#x2013;32490. 10.1074/jbc.M704314200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M704314200</ArticleId><ArticleId IdType="pubmed">17823119</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblum L. T.; et al. Mutation of the caspase-3 cleavage site in the astroglial glutamate transporter EAAT2 delays disease progression and extends lifespan in the SOD1-G93A mouse model of ALS. Exp. Neurol. 2017, 292, 145&#x2013;153. 10.1016/j.expneurol.2017.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2017.03.014</ArticleId><ArticleId IdType="pmc">PMC5433801</ArticleId><ArticleId IdType="pubmed">28342750</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane C. A.; et al. Alzheimer&#x2019;s disease. Eur. J. Neurol. 2018, 25, 59&#x2013;70. 10.1111/ene.13439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13439</ArticleId><ArticleId IdType="pubmed">28872215</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz Escudero J. M.; et al. Neuropsychiatric Symptoms as Predictors of Clinical Course in Neurodegeneration. A Longitudinal Study. Front Aging Neurosci. 2019, 11, 176.10.3389/fnagi.2019.00176.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00176</ArticleId><ArticleId IdType="pmc">PMC6668630</ArticleId><ArticleId IdType="pubmed">31396074</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C. R. Jr; et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018, 14, 535&#x2013;562. 10.1016/j.jalz.2018.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R.; et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 2015, 313, 1939&#x2013;1949. 10.1001/jama.2015.4669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.4669</ArticleId><ArticleId IdType="pmc">PMC4517678</ArticleId><ArticleId IdType="pubmed">25988463</ArticleId></ArticleIdList></Reference><Reference><Citation>Boza-Serrano A.; et al. Innate immune alterations are elicited in microglial cells before plaque deposition in the Alzheimer&#x2019;s disease mouse model 5xFAD. Sci. Rep. 2018, 8, 1550.10.1038/s41598-018-19699-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-19699-y</ArticleId><ArticleId IdType="pmc">PMC5784016</ArticleId><ArticleId IdType="pubmed">29367720</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreisl W. C. Discerning the relationship between microglial activation and Alzheimer&#x2019;s disease. Brain 2017, 140, 1825&#x2013;1828. 10.1093/brain/awx151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx151</ArticleId><ArticleId IdType="pubmed">29177498</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Reyes R. E.; et al. Involvement of Astrocytes in Alzheimer&#x2019;s Disease from a Neuroinflammatory and Oxidative Stress Perspective. Front Cell Neurosci. 2017, 10, 427.10.3389/fnmol.2017.00427.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00427</ArticleId><ArticleId IdType="pmc">PMC5742194</ArticleId><ArticleId IdType="pubmed">29311817</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A.; et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer&#x2019;s disease. Am. J. Pathol. 2011, 179, 1373&#x2013;1384. 10.1016/j.ajpath.2011.05.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2011.05.047</ArticleId><ArticleId IdType="pmc">PMC3157187</ArticleId><ArticleId IdType="pubmed">21777559</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A.; et al. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2011, 1, a006189.10.1101/cshperspect.a006189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006189</ArticleId><ArticleId IdType="pmc">PMC3234452</ArticleId><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Escartin C.; et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat. Neurosci. 2021, 24, 312&#x2013;325. 10.1038/s41593-020-00783-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00783-4</ArticleId><ArticleId IdType="pmc">PMC8007081</ArticleId><ArticleId IdType="pubmed">33589835</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Esparcia P.; et al. Glutamate Transporter GLT1 Expression in Alzheimer Disease and Dementia With Lewy Bodies. Front Aging Neurosci. 2018, 10, 122.10.3389/fnagi.2018.00122.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2018.00122</ArticleId><ArticleId IdType="pmc">PMC5932187</ArticleId><ArticleId IdType="pubmed">29755340</ArticleId></ArticleIdList></Reference><Reference><Citation>Viejo L.; et al. Systematic review of human post-mortem immunohistochemical studies and bioinformatics analyses unveil the complexity of astrocyte reaction in Alzheimer&#x2019;s disease. Neuropathol. Appl. Neurobiol. 2022, 48, e1275310.1111/nan.12753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12753</ArticleId><ArticleId IdType="pmc">PMC8766893</ArticleId><ArticleId IdType="pubmed">34297416</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckstrom H.; et al. Interindividual differences in the levels of the glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer&#x2019;s disease. J. Neurosci. Res. 1999, 55, 218&#x2013;229. 10.1002/(SICI)1097-4547(19990115)55:2&lt;218::AID-JNR9&gt;3.0.CO;2-L.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(19990115)55:2&lt;218::AID-JNR9&gt;3.0.CO;2-L</ArticleId><ArticleId IdType="pubmed">9972824</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood O. W. G.; et al. EAAT2 as a therapeutic research target in Alzheimer&#x2019;s disease: A systematic review. Front Neurosci. 2022, 16, 952096.10.3389/fnins.2022.952096.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2022.952096</ArticleId><ArticleId IdType="pmc">PMC9399514</ArticleId><ArticleId IdType="pubmed">36033606</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott H. A.; et al. Glutamate transporter variants reduce glutamate uptake in Alzheimer&#x2019;s disease. Neurobiol. Aging 2011, 32, 553.10.1016/j.neurobiolaging.2010.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.03.008</ArticleId><ArticleId IdType="pubmed">20416976</ArticleId></ArticleIdList></Reference><Reference><Citation>Trotti D.; et al. Glutamate transporters are oxidant-vulnerable: a molecular link between oxidative and excitotoxic neurodegeneration?. Trends Pharmacol. Sci. 1998, 19, 328&#x2013;334. 10.1016/S0165-6147(98)01230-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-6147(98)01230-9</ArticleId><ArticleId IdType="pubmed">9745361</ArticleId></ArticleIdList></Reference><Reference><Citation>Woltjer R. L.; et al. Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2010, 69, 667&#x2013;676. 10.1097/NEN.0b013e3181e24adb.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181e24adb</ArticleId><ArticleId IdType="pmc">PMC3097122</ArticleId><ArticleId IdType="pubmed">20535038</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontana I. C.; et al. Amyloid-beta oligomers in cellular models of Alzheimer&#x2019;s disease. J. Neurochem. 2020, 155, 348.10.1111/jnc.15030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15030</ArticleId><ArticleId IdType="pubmed">32320074</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R.; et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006, 7, 940&#x2013;946. 10.1038/sj.embor.7400784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400784</ArticleId><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E.; et al. Abnormal glutamate transport function in mutant amyloid precursor protein transgenic mice. Exp. Neurol. 2000, 163, 381&#x2013;387. 10.1006/exnr.2000.7386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.2000.7386</ArticleId><ArticleId IdType="pubmed">10833311</ArticleId></ArticleIdList></Reference><Reference><Citation>Schallier A.; et al. Region- and age-specific changes in glutamate transport in the AbetaPP23 mouse model for Alzheimer&#x2019;s disease. J. Alzheimers Dis. 2011, 24, 287&#x2013;300. 10.3233/JAD-2011-101005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-101005</ArticleId><ArticleId IdType="pubmed">21297271</ArticleId></ArticleIdList></Reference><Reference><Citation>Mookherjee P.; et al. GLT-1 loss accelerates cognitive deficit onset in an Alzheimer&#x2019;s disease animal model. J. Alzheimers Dis. 2011, 26, 447&#x2013;455. 10.3233/JAD-2011-110503.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-110503</ArticleId><ArticleId IdType="pmc">PMC3256092</ArticleId><ArticleId IdType="pubmed">21677376</ArticleId></ArticleIdList></Reference><Reference><Citation>Hefendehl J. K.; et al. Mapping synaptic glutamate transporter dysfunction in vivo to regions surrounding Abeta plaques by iGluSnFR two-photon imaging. Nat. Commun. 2016, 7, 13441.10.1038/ncomms13441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms13441</ArticleId><ArticleId IdType="pmc">PMC5114608</ArticleId><ArticleId IdType="pubmed">27834383</ArticleId></ArticleIdList></Reference><Reference><Citation>Audrain M.; et al. Alzheimer&#x2019;s disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression. Mol. Neurodegener. 2016, 11, 5.10.1186/s13024-016-0070-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0070-y</ArticleId><ArticleId IdType="pmc">PMC4709894</ArticleId><ArticleId IdType="pubmed">26759118</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulijewicz-Nawrot M.; et al. Astrocytes and glutamate homoeostasis in Alzheimer&#x2019;s disease: a decrease in glutamine synthetase, but not in glutamate transporter-1, in the prefrontal cortex. Ann. Neurol. 2013, 5, 273&#x2013;282. 10.1042/AN20130017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/AN20130017</ArticleId><ArticleId IdType="pmc">PMC3791522</ArticleId><ArticleId IdType="pubmed">24059854</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong H.; et al. Amyloid-beta peptide decreases expression and function of glutamate transporters in nervous system cells. Int. J. Biochem. Cell Biol. 2017, 85, 75&#x2013;84. 10.1016/j.biocel.2017.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2017.01.017</ArticleId><ArticleId IdType="pubmed">28189841</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava I.; et al. Reducing Glutamate Uptake in Rat Hippocampal Slices Enhances Astrocytic Membrane Depolarization While Down-Regulating CA3-CA1 Synaptic Response. Front Synaptic Neurosci. 2020, 12, 37.10.3389/fnsyn.2020.00037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnsyn.2020.00037</ArticleId><ArticleId IdType="pmc">PMC7461906</ArticleId><ArticleId IdType="pubmed">32973483</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoltowska K. M.; et al. Novel interaction between Alzheimer&#x2019;s disease-related protein presenilin 1 and glutamate transporter 1. Sci. Rep. 2018, 8, 8718.10.1038/s41598-018-26888-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-26888-2</ArticleId><ArticleId IdType="pmc">PMC5992168</ArticleId><ArticleId IdType="pubmed">29880815</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian G.; et al. Increased expression of cholesterol 24S-hydroxylase results in disruption of glial glutamate transporter EAAT2 association with lipid rafts: a potential role in Alzheimer&#x2019;s disease. J. Neurochem. 2010, 113, 978&#x2013;989. 10.1111/j.1471-4159.2010.06661.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.06661.x</ArticleId><ArticleId IdType="pmc">PMC3010752</ArticleId><ArticleId IdType="pubmed">20193040</ArticleId></ArticleIdList></Reference><Reference><Citation>Sompol P.; et al. Calcineurin/NFAT Signaling in Activated Astrocytes Drives Network Hyperexcitability in Abeta-Bearing Mice. J. Neurosci. 2017, 37, 6132&#x2013;6148. 10.1523/JNEUROSCI.0877-17.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0877-17.2017</ArticleId><ArticleId IdType="pmc">PMC5481945</ArticleId><ArticleId IdType="pubmed">28559377</ArticleId></ArticleIdList></Reference><Reference><Citation>Habchi J.; et al. Cholesterol catalyses Abeta42 aggregation through a heterogeneous nucleation pathway in the presence of lipid membranes. Nat. Chem. 2018, 10, 673&#x2013;683. 10.1038/s41557-018-0031-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41557-018-0031-x</ArticleId><ArticleId IdType="pubmed">29736006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki K.; et al. Excitatory amino acid transporter 2 associates with phosphorylated tau and is localized in neurofibrillary tangles of tauopathic brains. FEBS Lett. 2009, 583, 2194&#x2013;2200. 10.1016/j.febslet.2009.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2009.06.015</ArticleId><ArticleId IdType="pubmed">19527721</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabir D. V.; et al. Impaired glutamate transport in a mouse model of tau pathology in astrocytes. J. Neurosci. 2006, 26, 644&#x2013;654. 10.1523/JNEUROSCI.3861-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3861-05.2006</ArticleId><ArticleId IdType="pmc">PMC6674424</ArticleId><ArticleId IdType="pubmed">16407562</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Puma D. D.; et al. Extracellular tau oligomers affect extracellular glutamate handling by astrocytes through downregulation of GLT-1 expression and impairment of NKA1A2 function. Neuropathol. Appl. Neurobiol. 2022, 48, e1281110.1111/nan.12811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12811</ArticleId><ArticleId IdType="pmc">PMC9262805</ArticleId><ArticleId IdType="pubmed">35274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepeda C.; et al. The corticostriatal pathway in Huntington&#x2019;s disease. Prog. Neurobiol. 2007, 81, 253&#x2013;271. 10.1016/j.pneurobio.2006.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2006.11.001</ArticleId><ArticleId IdType="pmc">PMC1913635</ArticleId><ArticleId IdType="pubmed">17169479</ArticleId></ArticleIdList></Reference><Reference><Citation>Faideau M.; et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington&#x2019;s disease subjects. Hum. Mol. Genet. 2010, 19, 3053&#x2013;3067. 10.1093/hmg/ddq212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq212</ArticleId><ArticleId IdType="pmc">PMC2901144</ArticleId><ArticleId IdType="pubmed">20494921</ArticleId></ArticleIdList></Reference><Reference><Citation>Arzberger T.; et al. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington&#x2019;s disease-an in situ hybridization study. J. Neuropathol. Exp. Neurol. 1997, 56, 440&#x2013;454. 10.1097/00005072-199704000-00013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199704000-00013</ArticleId><ArticleId IdType="pubmed">9100675</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinheiro Campos A. Effect of Subthalamic Stimulation and Electrode Implantation in the Striatal Microenvironment in a Parkinson&#x2019;s Disease Rat Model. Int. J. Mol.Sci. 2022, 23, 12116.10.3390/ijms232012116.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232012116</ArticleId><ArticleId IdType="pmc">PMC9603133</ArticleId><ArticleId IdType="pubmed">36292973</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng L.; et al. Erythrocytic alpha-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson&#x2019;s disease pathogenesis. Acta Neuropathol. Commun. 2020, 8, 102.10.1186/s40478-020-00983-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-00983-w</ArticleId><ArticleId IdType="pmc">PMC7346449</ArticleId><ArticleId IdType="pubmed">32641150</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.; et al. Generation of a Novel Mouse Model of Parkinson&#x2019;s Disease via Targeted Knockdown of Glutamate Transporter GLT-1 in the Substantia Nigra. ACS Chem. Neurosci. 2020, 11, 406&#x2013;417. 10.1021/acschemneuro.9b00609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.9b00609</ArticleId><ArticleId IdType="pubmed">31909584</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren C.; et al. Induction of Parkinsonian-Like Changes via Targeted Downregulation of Astrocytic Glutamate Transporter GLT-1 in the Striatum. J. Parkinsons Dis. 2022, 12, 295&#x2013;314. 10.3233/JPD-212640.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-212640</ArticleId><ArticleId IdType="pubmed">34719508</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei L.; et al. Wnt1 Promotes EAAT2 Expression and Mediates the Protective Effects of Astrocytes on Dopaminergic Cells in Parkinson&#x2019;s Disease. Neural Plast. 2019, 2019, 1247276.10.1155/2019/1247276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/1247276</ArticleId><ArticleId IdType="pmc">PMC6754970</ArticleId><ArticleId IdType="pubmed">31582965</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Y.; et al. Exercise increases striatal Glu reuptake and improves motor dysfunction in 6-OHDA-induced Parkinson&#x2019;s disease rats. Exp. Brain Res. 2021, 239, 3277&#x2013;3287. 10.1007/s00221-021-06186-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00221-021-06186-6</ArticleId><ArticleId IdType="pubmed">34463828</ArticleId></ArticleIdList></Reference><Reference><Citation>Iovino L.; et al. Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson&#x2019;s disease. Acta Neuropathol. 2022, 144, 81&#x2013;106. 10.1007/s00401-022-02437-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-022-02437-0</ArticleId><ArticleId IdType="pmc">PMC9217889</ArticleId><ArticleId IdType="pubmed">35596783</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed M. A.; et al. Astrogliosis in aging and Parkinson&#x2019;s disease dementia: a new clinical study with (11) C-BU99008 PET. Brain Commun. 2022, 4, fcac199.10.1093/braincomms/fcac199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcac199</ArticleId><ArticleId IdType="pmc">PMC9445175</ArticleId><ArticleId IdType="pubmed">36072646</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson H.; et al. Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson&#x2019;s disease: an in vivo11C-BU99008 PET study. Brain 2019, 142, 3116&#x2013;3128. 10.1093/brain/awz260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz260</ArticleId><ArticleId IdType="pubmed">31504212</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi E.; et al. Activated forms of astrocytes with higher GLT-1 expression are associated with cognitive normal subjects with Alzheimer pathology in human brain. Sci. Rep. 2018, 8, 1712.10.1038/s41598-018-19442-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-19442-7</ArticleId><ArticleId IdType="pmc">PMC5786045</ArticleId><ArticleId IdType="pubmed">29374250</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews D. C.; et al. Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer&#x2019;s disease. Brain 2021, 144, 3742&#x2013;3755. 10.1093/brain/awab222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab222</ArticleId><ArticleId IdType="pmc">PMC8719848</ArticleId><ArticleId IdType="pubmed">34145880</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan S.; et al. Ceftriaxone Improves Cognitive Function and Upregulates GLT-1-Related Glutamate-Glutamine Cycle in APP/PS1Mice. J.Alzheimers Dis. 2018, 66, 1731&#x2013;1743. 10.3233/JAD-180708.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180708</ArticleId><ArticleId IdType="pubmed">30452416</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamidi N.; et al. Effect of ceftriaxone on paired-pulse response and long-term potentiation of hippocampal dentate gyrus neurons in rats with Alzheimer-like disease. Life Sci. 2019, 238, 116969.10.1016/j.lfs.2019.116969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2019.116969</ArticleId><ArticleId IdType="pubmed">31628912</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan S.; et al. Ceftriaxone regulates glutamate production and vesicular assembly in presynaptic terminals through GLT-1 in APP/PS1 mice. Neurobiol. Learn. Mem. 2021, 183, 107480.10.1016/j.nlm.2021.107480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nlm.2021.107480</ArticleId><ArticleId IdType="pubmed">34153453</ArticleId></ArticleIdList></Reference><Reference><Citation>Chotibut T.; et al. Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson&#x2019;s disease model. Mov. Disord. 2017, 32, 1547&#x2013;1556. 10.1002/mds.27077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27077</ArticleId><ArticleId IdType="pmc">PMC5681381</ArticleId><ArticleId IdType="pubmed">28631864</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry J. D.; et al. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One 2013, 8, e6117710.1371/journal.pone.0061177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0061177</ArticleId><ArticleId IdType="pmc">PMC3629222</ArticleId><ArticleId IdType="pubmed">23613806</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M. E.; et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014, 13, 1083&#x2013;1091. 10.1016/S1474-4422(14)70222-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70222-4</ArticleId><ArticleId IdType="pmc">PMC4216315</ArticleId><ArticleId IdType="pubmed">25297012</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli E.; et al. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur. J. Pharmacol. 2008, 578, 171&#x2013;176. 10.1016/j.ejphar.2007.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2007.10.023</ArticleId><ArticleId IdType="pubmed">18036519</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbone M.; et al. Riluzole elevates GLT-1 activity and levels in striatal astrocytes. Neurochem. Int. 2012, 60, 31&#x2013;38. 10.1016/j.neuint.2011.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2011.10.017</ArticleId><ArticleId IdType="pmc">PMC3430367</ArticleId><ArticleId IdType="pubmed">22080156</ArticleId></ArticleIdList></Reference><Reference><Citation>Zschocke J.; et al. Differential promotion of glutamate transporter expression and function by glucocorticoids in astrocytes from various brain regions. J. Biol. Chem. 2005, 280, 34924&#x2013;34932. 10.1074/jbc.M502581200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M502581200</ArticleId><ArticleId IdType="pubmed">16079146</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E.; et al. Transforming growth factor-alpha mediates estrogen-induced upregulation of glutamate transporter GLT-1 in rat primary astrocytes. Glia 2012, 60, 1024&#x2013;1036. 10.1002/glia.22329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22329</ArticleId><ArticleId IdType="pmc">PMC3353324</ArticleId><ArticleId IdType="pubmed">22488924</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki P.; et al. Mechanism of raloxifene-induced upregulation of glutamate transporters in rat primary astrocytes. Glia 2014, 62, 1270&#x2013;1283. 10.1002/glia.22679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22679</ArticleId><ArticleId IdType="pmc">PMC4061260</ArticleId><ArticleId IdType="pubmed">24782323</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki P.; et al. cAMP response element-binding protein (CREB) and nuclear factor kappaB mediate the tamoxifen-induced up-regulation of glutamate transporter 1 (GLT-1) in rat astrocytes. J. Biol. Chem. 2013, 288, 28975&#x2013;28986. 10.1074/jbc.M113.483826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.483826</ArticleId><ArticleId IdType="pmc">PMC3789995</ArticleId><ArticleId IdType="pubmed">23955341</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung J. H. Y.; et al. EAAT2 Expression in the Hippocampus, Subiculum, Entorhinal Cortex and Superior Temporal Gyrus in Alzheimer&#x2019;s Disease. Front Cell Neurosci. 2021, 15, 702824.10.3389/fncel.2021.702824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.702824</ArticleId><ArticleId IdType="pmc">PMC8475191</ArticleId><ArticleId IdType="pubmed">34588956</ArticleId></ArticleIdList></Reference><Reference><Citation>Colton C. K.; et al. Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicity. J. Biomol. Screen. 2010, 15, 653&#x2013;662. 10.1177/1087057110370998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1087057110370998</ArticleId><ArticleId IdType="pmc">PMC3016154</ArticleId><ArticleId IdType="pubmed">20508255</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing X.; et al. Structure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators. Bioorg. Med. Chem. Lett. 2011, 21, 5774&#x2013;5777. 10.1016/j.bmcl.2011.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2011.08.009</ArticleId><ArticleId IdType="pmc">PMC3172717</ArticleId><ArticleId IdType="pubmed">21875806</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong Q.; et al. Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection. J. Clin. Invest. 2014, 124, 1255&#x2013;1267. 10.1172/JCI66163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI66163</ArticleId><ArticleId IdType="pmc">PMC3938250</ArticleId><ArticleId IdType="pubmed">24569372</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer T.; et al. Alternative splicing of the glutamate transporter EAAT2 (GLT-1). Neurosci. Lett. 1998, 241, 68&#x2013;70. 10.1016/S0304-3940(97)00973-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(97)00973-7</ArticleId><ArticleId IdType="pubmed">9502218</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K.; et al. Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for Alzheimer&#x2019;s disease. J. Exp. Med. 2015, 212, 319&#x2013;332. 10.1084/jem.20140413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20140413</ArticleId><ArticleId IdType="pmc">PMC4354363</ArticleId><ArticleId IdType="pubmed">25711212</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui X.; et al. Sulbactam Plays Neuronal Protective Effect Against Brain Ischemia via Upregulating GLT1 in Rats. Mol. Neurobiol. 2015, 51, 1322&#x2013;1333. 10.1007/s12035-014-8809-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-8809-3</ArticleId><ArticleId IdType="pubmed">25064054</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi J.; et al. Sulbactam Protects Hippocampal Neurons Against Oxygen-Glucose Deprivation by Up-Regulating Astrocytic GLT-1 via p38 MAPK Signal Pathway. Front Cell Neurosci. 2018, 11, 281.10.3389/fnmol.2018.00281.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00281</ArticleId><ArticleId IdType="pmc">PMC6104165</ArticleId><ArticleId IdType="pubmed">30158854</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q. X.; Yang T. D. Amitriptyline upregulates EAAT1 and EAAT2 in neuropathic pain rats. Brain Res. Bull. 2010, 81, 424&#x2013;427. 10.1016/j.brainresbull.2009.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2009.09.006</ArticleId><ArticleId IdType="pubmed">19772901</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu A. Y.; et al. Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival. J. Biol. Chem. 2011, 286, 2785&#x2013;2794. 10.1074/jbc.M110.158220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.158220</ArticleId><ArticleId IdType="pmc">PMC3024774</ArticleId><ArticleId IdType="pubmed">21098017</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganel R.; et al. Selective up-regulation of the glial Na+-dependent glutamate transporter GLT1 by a neuroimmunophilin ligand results in neuroprotection. Neurobiol. Dis. 2006, 21, 556&#x2013;567. 10.1016/j.nbd.2005.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2005.08.014</ArticleId><ArticleId IdType="pubmed">16274998</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X.; et al. Effect of MS-153 on the acquisition and expression of conditioned fear in rats. Eur. J. Pharmacol. 2004, 505, 145&#x2013;149. 10.1016/j.ejphar.2004.10.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2004.10.041</ArticleId><ArticleId IdType="pubmed">15556147</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa T.; et al. Effect of MS-153, a glutamate transporter activator, on the conditioned rewarding effects of morphine, methamphetamine and cocaine in mice. Behav. Brain Res. 2005, 156, 233&#x2013;239. 10.1016/j.bbr.2004.05.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2004.05.029</ArticleId><ArticleId IdType="pubmed">15582109</ArticleId></ArticleIdList></Reference><Reference><Citation>Aal-Aaboda M.; et al. Effects of (R)-(&#x2212;)-5-methyl-1-nicotinoyl-2-pyrazoline on glutamate transporter 1 and cysteine/glutamate exchanger as well as ethanol drinking behavior in male, alcohol-preferring rats. J. Neurosci.Res. 2015, 93, 930&#x2013;937. 10.1002/jnr.23554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.23554</ArticleId><ArticleId IdType="pmc">PMC4397131</ArticleId><ArticleId IdType="pubmed">25601490</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontana A. C.; et al. Neuroprotective Effects of the Glutamate Transporter Activator (R)-(&#x2212;)-5-methyl-1-nicotinoyl-2-pyrazoline (MS-153) following Traumatic Brain Injury in the Adult Rat. J. Neurotrauma 2016, 33, 1073&#x2013;1083. 10.1089/neu.2015.4079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2015.4079</ArticleId><ArticleId IdType="pmc">PMC4892232</ArticleId><ArticleId IdType="pubmed">26200170</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimada F.; et al. The neuroprotective agent MS-153 stimulates glutamate uptake. Eur. J. Pharmacol. 1999, 386, 263&#x2013;270. 10.1016/S0014-2999(99)00735-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-2999(99)00735-9</ArticleId><ArticleId IdType="pubmed">10618478</ArticleId></ArticleIdList></Reference><Reference><Citation>Uenishi H.; et al. Ion channel modulation as the basis for neuroprotective action of MS-153. Ann. N.Y. Acad. Sci. 1999, 890, 385&#x2013;399. 10.1111/j.1749-6632.1999.tb08018.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1999.tb08018.x</ArticleId><ArticleId IdType="pubmed">10668444</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcucci R. M.; et al. Novel Positive Allosteric Modulators of Glutamate Transport Have Neuroprotective Properties in an in Vitro Excitotoxic Model. ACS Chem. Neurosci. 2019, 10, 3437&#x2013;3453. 10.1021/acschemneuro.9b00061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.9b00061</ArticleId><ArticleId IdType="pmc">PMC7099866</ArticleId><ArticleId IdType="pubmed">31257852</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile A.; et al. Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake. J. Neurochem. 2018, 15, 5.10.1186/s12974-017-1048-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-017-1048-6</ArticleId><ArticleId IdType="pmc">PMC5756343</ArticleId><ArticleId IdType="pubmed">29304807</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontana A. C.; et al. Enhancing glutamate transport: mechanism of action of Parawixin1, a neuroprotective compound from Parawixia bistriata spider venom. Mol. Pharmacol. 2007, 72, 1228&#x2013;1237. 10.1124/mol.107.037127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.107.037127</ArticleId><ArticleId IdType="pubmed">17646426</ArticleId></ArticleIdList></Reference><Reference><Citation>Forster Y. M.; et al. Elucidation of the Structure and Synthesis of Neuroprotective Low Molecular Mass Components of the Parawixia bistriata Spider Venom. ACS Chem. Neurosci. 2020, 11, 1573&#x2013;1596. 10.1021/acschemneuro.0c00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00007</ArticleId><ArticleId IdType="pubmed">32343555</ArticleId></ArticleIdList></Reference><Reference><Citation>Kortagere S.; et al. Identification of Novel Allosteric Modulators of Glutamate Transporter EAAT2. ACS Chem. Neurosci. 2018, 9, 522&#x2013;534. 10.1021/acschemneuro.7b00308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.7b00308</ArticleId><ArticleId IdType="pubmed">29140675</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S.; et al. Design and Characterization of Novel Small Molecule Activators of Excitatory Amino Acid Transporter 2. ACS Med. Chem. Lett. 2022, 13, 1628&#x2013;1633. 10.1021/acsmedchemlett.2c00304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsmedchemlett.2c00304</ArticleId><ArticleId IdType="pmc">PMC9575181</ArticleId><ArticleId IdType="pubmed">36262387</ArticleId></ArticleIdList></Reference><Reference><Citation>Abram M.; et al. Discovery of (R)-N-Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide [(R)-AS-1], a Novel Orally Bioavailable EAAT2 Modulator with Drug-like Properties and Potent Antiseizure Activity In Vivo. J. Med. Chem. 2022, 65, 11703&#x2013;11725. 10.1021/acs.jmedchem.2c00534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.2c00534</ArticleId><ArticleId IdType="pmc">PMC9469208</ArticleId><ArticleId IdType="pubmed">35984707</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriza J. L.; et al. Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J. Neurosci. 1994, 14, 5559&#x2013;5569. 10.1523/JNEUROSCI.14-09-05559.1994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.14-09-05559.1994</ArticleId><ArticleId IdType="pmc">PMC6577102</ArticleId><ArticleId IdType="pubmed">7521911</ArticleId></ArticleIdList></Reference><Reference><Citation>Gegelashvili G.; Schousboe A. Cellular distribution and kinetic properties of high-affinity glutamate transporters. Brain Res. Bull. 1998, 45, 233&#x2013;238. 10.1016/S0361-9230(97)00417-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0361-9230(97)00417-6</ArticleId><ArticleId IdType="pubmed">9510415</ArticleId></ArticleIdList></Reference><Reference><Citation>Besson M. T.; et al. Selective high-affinity transport of aspartate by a Drosophila homologue of the excitatory amino-acid transporters. Curr. Biol. 2000, 10, 207&#x2013;210. 10.1016/S0960-9822(00)00339-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-9822(00)00339-0</ArticleId><ArticleId IdType="pubmed">10704415</ArticleId></ArticleIdList></Reference><Reference><Citation>Balcar V. J.; et al. Stereospecificity of the inhibition of L-glutamate and L-aspartate high affinity uptake in rat brain slices by threo-3-hydroxyaspartate. J. Neurochem. 1977, 28, 1145&#x2013;1146. 10.1111/j.1471-4159.1977.tb10682.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1977.tb10682.x</ArticleId><ArticleId IdType="pubmed">864464</ArticleId></ArticleIdList></Reference><Reference><Citation>Marini A.; Novelli A. DL-threo-3-hydroxyaspartate reduces NMDA receptor activation by glutamate in cultured neurons. Eur. J. Pharmacol. 1991, 194, 131&#x2013;132. 10.1016/0014-2999(91)90136-E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-2999(91)90136-E</ArticleId><ArticleId IdType="pubmed">1676372</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H.; et al. Chemoenzymatic Synthesis and Pharmacological Characterization of Functionalized Aspartate Analogues As Novel Excitatory Amino Acid Transporter Inhibitors. J. Med. Chem. 2018, 61, 7741&#x2013;7753. 10.1021/acs.jmedchem.8b00700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.8b00700</ArticleId><ArticleId IdType="pmc">PMC6139576</ArticleId><ArticleId IdType="pubmed">30011368</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimamoto K.; et al. DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol. Pharmacol. 1998, 53, 195&#x2013;201. 10.1124/mol.53.2.195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.53.2.195</ArticleId><ArticleId IdType="pubmed">9463476</ArticleId></ArticleIdList></Reference><Reference><Citation>Cechova S.; Zuo Z. Inhibition of glutamate transporters increases the minimum alveolar concentration for isoflurane in rats. Br. J. Anaesth. 2006, 97, 192&#x2013;195. 10.1093/bja/ael152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/ael152</ArticleId><ArticleId IdType="pubmed">16793777</ArticleId></ArticleIdList></Reference><Reference><Citation>Montiel T.; et al. Differential effects of the substrate inhibitor l-trans-pyrrolidine-2,4-dicarboxylate (PDC) and the non-substrate inhibitor DL-threo-beta-benzyloxyaspartate (DL-TBOA) of glutamate transporters on neuronal damage and extracellular amino acid levels in rat brain in vivo. Neuroscience 2005, 133, 667&#x2013;678. 10.1016/j.neuroscience.2004.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2004.11.020</ArticleId><ArticleId IdType="pubmed">15890455</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonde C.; et al. Neurotoxic and neuroprotective effects of the glutamate transporter inhibitor DL-threo-beta-benzyloxyaspartate (DL-TBOA) during physiological and ischemia-like conditions. Neurochem. Int. 2003, 43, 371&#x2013;380. 10.1016/S0197-0186(03)00024-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-0186(03)00024-X</ArticleId><ArticleId IdType="pubmed">12742081</ArticleId></ArticleIdList></Reference><Reference><Citation>Shigeri Y.; et al. Effects of threo-beta-hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5). J. Neurochem. 2001, 79, 297&#x2013;302. 10.1046/j.1471-4159.2001.00588.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2001.00588.x</ArticleId><ArticleId IdType="pubmed">11677257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen J. C.; et al. beta-Sulfonamido Functionalized Aspartate Analogues as Excitatory Amino Acid Transporter Inhibitors: Distinct Subtype Selectivity Profiles Arising from Subtle Structural Differences. J. Med. Chem. 2016, 59, 8771&#x2013;8786. 10.1021/acs.jmedchem.6b01066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.6b01066</ArticleId><ArticleId IdType="pubmed">27636002</ArticleId></ArticleIdList></Reference><Reference><Citation>Leighton B. H.; et al. A hydrophobic domain in glutamate transporters forms an extracellular helix associated with the permeation pathway for substrates. J. Biol. Chem. 2002, 277, 29847&#x2013;29855. 10.1074/jbc.M202508200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M202508200</ArticleId><ArticleId IdType="pubmed">12015317</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimamoto K.; et al. Characterization of novel L-threo-beta-benzyloxyaspartate derivatives, potent blockers of the glutamate transporters. Mol. Pharmacol. 2004, 65, 1008&#x2013;1015. 10.1124/mol.65.4.1008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.65.4.1008</ArticleId><ArticleId IdType="pubmed">15044631</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzo L.; Chatton J. Y. Inhibitory effects of (2S, 3S)-3-[3-[4-(trifluoromethyl) benzoylamino]benzyloxy]aspartate (TFB-TBOA) on the astrocytic sodium responses to glutamate. Brain Res. 2010, 1316, 27&#x2013;34. 10.1016/j.brainres.2009.12.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2009.12.028</ArticleId><ArticleId IdType="pubmed">20026319</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuenberger M.; et al. Concise Asymmetric Synthesis and Pharmacological Characterization of All Stereoisomers of Glutamate Transporter Inhibitor TFB-TBOA and Synthesis of EAAT Photoaffinity Probes. ACS Chem. Neurosci. 2016, 7, 534&#x2013;539. 10.1021/acschemneuro.5b00311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.5b00311</ArticleId><ArticleId IdType="pubmed">26918289</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenfield A.; et al. Synthesis and biological activities of aryl-ether-, biaryl-, and fluorene-aspartic acid and diaminopropionic acid analogs as potent inhibitors of the high-affinity glutamate transporter EAAT-2. Bioorg. Med. Chem. Lett. 2005, 15, 4985&#x2013;4988. 10.1016/j.bmcl.2005.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2005.08.003</ArticleId><ArticleId IdType="pubmed">16165356</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunlop J.; et al. Characterization of novel aryl-ether, biaryl, and fluorene aspartic acid and diaminopropionic acid analogs as potent inhibitors of the high-affinity glutamate transporter EAAT2. Mol. Pharmacol. 2005, 68, 974&#x2013;982. 10.1124/mol.105.012005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.105.012005</ArticleId><ArticleId IdType="pubmed">16014807</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston G. A.; et al. Action of the neurotoxin kainic acid on high affinity uptake of L-glutamic acid in rat brain slices. J. Neurochem. 1979, 32, 121&#x2013;127. 10.1111/j.1471-4159.1979.tb04518.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1979.tb04518.x</ArticleId><ArticleId IdType="pubmed">759563</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon J. R.; et al. Binding of [3H] kainic acid, and analogue of Lglutamate, to brain membranes. J. Neurochem. 1976, 26, 141&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">1255165</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouix E.; et al. Reverse glial glutamate uptake triggers neuronal cell death through extrasynaptic NMDA receptor activation. Mol. Cell. Neurosci. 2009, 40, 463&#x2013;473. 10.1016/j.mcn.2009.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2009.01.002</ArticleId><ArticleId IdType="pubmed">19340933</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch H. P.; et al. Differentiation of substrate and nonsubstrate inhibitors of the high-affinity, sodium-dependent glutamate transporters. Mol. Pharmacol. 1999, 56, 1095&#x2013;1104. 10.1124/mol.56.6.1095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.56.6.1095</ArticleId><ArticleId IdType="pubmed">10570036</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenberg R. J.; et al. Contrasting modes of action of methylglutamate derivatives on the excitatory amino acid transporters, EAAT1 and EAAT2. Mol. Pharmacol. 1997, 51, 809&#x2013;815. 10.1124/mol.51.5.809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.51.5.809</ArticleId><ArticleId IdType="pubmed">9145919</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunlop J.; et al. WAY-855 (3-amino-tricyclo[2.2.1.02.6]heptane-1,3-dicarboxylic acid): a novel, EAAT2-preferring, nonsubstrate inhibitor of high-affinity glutamate uptake. Br. J. Pharmacol. 2003, 140, 839&#x2013;846. 10.1038/sj.bjp.0705509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0705509</ArticleId><ArticleId IdType="pmc">PMC1574101</ArticleId><ArticleId IdType="pubmed">14517179</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagot E.; et al. Chemo-enzymatic synthesis of (2S,4R)-2-amino-4-(3-(2,2-diphenylethylamino)-3-oxopropyl) pentanedioic acid: a novel selective inhibitor of human excitatory amino acid transporter subtype 2. J. Med. Chem. 2008, 51, 4085&#x2013;4092. 10.1021/jm800091e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm800091e</ArticleId><ArticleId IdType="pubmed">18578477</ArticleId></ArticleIdList></Reference><Reference><Citation>Sander C. Y.; Hesse S. News and views on in-vivo imaging of neurotransmission using PET and MRI. Q. J. Nucl. Med. Mol. Imaging. 2017, 61, 414&#x2013;428. 10.23736/S1824-4785.17.03019-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S1824-4785.17.03019-9</ArticleId><ArticleId IdType="pmc">PMC5916779</ArticleId><ArticleId IdType="pubmed">28750497</ArticleId></ArticleIdList></Reference><Reference><Citation>Gee A. D.et al.Small Molecules as Radiopharmaceutical Vectors. In Radiopharmaceutical Chemistry, Lewis J. S.; Windhorst A. D.; Zeglis B. M., Eds.; Springer International Publishing: Cham, 2019; pp 119&#x2013;136.</Citation></Reference><Reference><Citation>Eckelman W. C.; et al. Receptor-binding radiotracers: a class of potential radiopharmaceuticals. J. Nucl. Med. 1979, 20, 350&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">43884</ArticleId></ArticleIdList></Reference><Reference><Citation>Luurtsema G.; et al. EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality. EJNMMI Radiopharm. Chem. 2021, 6, 34.10.1186/s41181-021-00149-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41181-021-00149-6</ArticleId><ArticleId IdType="pmc">PMC8502193</ArticleId><ArticleId IdType="pubmed">34628570</ArticleId></ArticleIdList></Reference><Reference><Citation>Wager T. T.; et al. Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery. ACS Chem. Neurosci. 2016, 7, 767&#x2013;775. 10.1021/acschemneuro.6b00029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.6b00029</ArticleId><ArticleId IdType="pubmed">26991242</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark D. E. In silico prediction of blood-brain barrier permeation. Drug Discovery Today 2003, 8, 927&#x2013;933. 10.1016/S1359-6446(03)02827-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1359-6446(03)02827-7</ArticleId><ArticleId IdType="pubmed">14554156</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan H.; Silverman R. B. Structural modifications of (1S,3S)-3-amino-4-difluoromethylenecyclopentanecarboxylic acid, a potent irreversible inhibitor of GABA aminotransferase. Bioorg. Med. Chem. Lett. 2007, 17, 1651&#x2013;1654. 10.1016/j.bmcl.2006.12.119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2006.12.119</ArticleId><ArticleId IdType="pmc">PMC1853296</ArticleId><ArticleId IdType="pubmed">17267220</ArticleId></ArticleIdList></Reference><Reference><Citation>Galante E.; et al. Development of purine-derived 18F-labeled pro-drug tracers for imaging of MRP1 activity with PET. J. Med. Chem. 2014, 57, 1023&#x2013;1032. 10.1021/jm401764a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm401764a</ArticleId><ArticleId IdType="pmc">PMC3963453</ArticleId><ArticleId IdType="pubmed">24456310</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>